Drugs / TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01955460 | Oct 2014 → Oct 2027 expected | cutaneous melanoma, metastatic melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02650986 | Jul 2017 → Mar 2021 overdue | cutaneous melanoma, fallopian tube carcinoma, metastatic melanoma, ovarian carcinoma +2 | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02650986 ↗ |
| Action | Deplete | “Adding these genes to the T cells may help them kill more tumor cells when they are put back in the body.” NCT01955460 ↗ |
| Modality | Cell therapy | “genetically modified T-cells” NCT01955460 ↗ |
| Route | Intravenous | “Given IV” NCT01955460 ↗ |